Taiwan Cobia

Cobia Biotech is a Taiwanese medical technology company focused on revolutionizing molecular diagnostics through its proprietary microfluidic platform. Founded as a spin-off from research at Academia Sinica, the company develops point-of-care testing (POCT) systems that deliver PCR-level sensitivity with the speed of rapid antigen tests. Their core "Cobia" system integrates sample preparation and nucleic acid amplification into a compact, automated device suitable for decentralized healthcare settings. The company's initial product line targets respiratory pathogens, including SARS-CoV-2 and influenza, providing critical tools for rapid outbreak management. Cobia Biotech is committed to expanding its diagnostic menu to include oncology and personalized medicine applications.